A Phase II Study of Bortezomib/Dexamethasone Followed by Lenalidomide in Nonresponders as Initial Treatment for Multiple Myeloma

Protocol
13-064
Full Title
Response Adapted Therapy with Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients with Multiple Myeloma
Phase
II
Purpose

Bortezomib, dexamethasone, and lenalidomide are often given together to treat newly diagnosed multiple myeloma (a cancer of the bone marrow). However, this combination of three drugs is associated with significant side effects. Doctors may be able to achieve the same results using only two drugs and add the third drug only in patients who do not respond to the two-drug combination.

In this study, researchers will first give patients just two of the drugs (bortezomib and dexamethasone). Patients will only receive lenalidomide if their myeloma is not well controlled with bortezomib and dexamethasone alone. Doctors hope that giving the myeloma drugs in this way will be as effective as using all three drugs at the same time from the beginning, but with less side effects.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must be newly diagnosed with symptomatic multiple myeloma and may not have received prior treatment.
  • Patients must be able to be ambulatory for more than half of their normal waking hours.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Hani Hassoun at 212-639-3228.

Disease(s)
Hematology: Multiple Myeloma
Related Diseases